Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2664MR)

This product GTTS-WQ2664MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Non-small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ2664MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5339MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ7220MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ6628MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ5983MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CLLB8
GTTS-WQ16002MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ13167MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04518600
GTTS-WQ1367MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-874
GTTS-WQ3760MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY-1834942
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW